Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis - Report - MDSpire
Advertisement
Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis
Clinical Report: Evaluating the Safety and Effectiveness of Advanced Combination Treatments for Adult Inflammatory Bowel Disease
Overview
This systematic review and meta-analysis evaluates the safety of advanced combination therapy (ACT) in adults with inflammatory bowel disease (IBD), revealing low rates of serious adverse events (SAEs) and treatment discontinuations.
Background
Inflammatory bowel disease (IBD) presents significant challenges in treatment, with high rates of treatment failure and a complex patient population. Advanced combination therapies (ACTs) are increasingly utilized in refractory cases.
Data Highlights
Outcome
Rate (%)
95% CI
Serious Adverse Events (SAEs) for anti-TNFa plus integrin inhibitors
2.7
0.22 to 6.86
Treatment Discontinuations
6.38
2.36 to 11.58
Key Findings
Fifty-two studies with 2022 participants were included in the analysis.
The most common combinations were anti-TNFa plus integrin inhibitors and IL-23 plus integrin inhibitors.
Pooled analyses indicated low rates of SAEs and treatment discontinuations.
Evidence certainty was rated very low due to small sample sizes and substantial heterogeneity.
Robust conclusions regarding safety and efficacy cannot be made based on the current evidence.
Clinical Implications
Clinicians should be aware of the low certainty of evidence when making treatment decisions.
Conclusion
The evidence is limited and further studies are necessary to establish the safety and efficacy of ACT.
